| Primary | Change From Baseline in the 24-item Hamilton Depression Scale Total Score At Week 8 | The 24-item Hamilton Depression Scale (HAM-D24) is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score range is from 0 to 74 where a higher score indicates a greater depressive state. Least squares (LS) means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis. | The full analysis set (FAS) included all patients who were randomized, received at least 1 dose of study drug, and had at least 1 post-baseline value for assessment of primary efficacy. A mixed model for repeated measurements (MMRM) based on observed cases was used. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline to Week 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 1 mg | Vortioxetine 1 mg, encapsulated tablets, orally, once daily for up 8 weeks. | | OG002 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up 8 weeks. | | OG003 | Vortioxetine 10 mg | Vortioxetine 10 mg, encapsulated tablets, orally, once daily for up 8 weeks. |
| | Units | Counts |
|---|
| Participants | - OG000128
- OG001124
- OG002129
- OG003
|
| | Title | Denominators | Categories |
|---|
| | | Title | Measurements |
|---|
| - OG000-11.30± 0.738
- OG001-14.82± 0.745
- OG002-15.42± 0.743
- OG003
|
|
| | Group IDs | Group Description | Statistical Method | Statistical Comment | P-Value | P-Value Comment | Parameter Type | Parameter Value | Dispersion Type | Dispersion Value | Confidence Interval Sides | Confidence Interval % | CI Lower Limit | CI Upper Limit | CI Lower Limit Comment | CI Upper Limit Comment | Estimate Comment | Tested Non-Inferiority | Non-Inferiority Type | Non-Inferiority Comment | Other Analysis Description |
|---|
| All statistical tests were 2-sided with the estimated P-values at the 5% level of significance. To control for multiplicity, a pre-specified sequential testing procedure was applied to compare 10 mg and 5 mg vortioxetine to placebo; as soon as an endpoint was non-significant at 0.05, the testing procedure stopped for all subsequent endpoints. | Mixed model for repeated measurements | P-values are from an MMRM model with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis. | <0.001 | Pre-specified sequential statistical testing procedure indicates that when p-value <0.05, hierarchical testing continues. | LS Mean Difference | -4.93 | | | 2-Sided | 95 | -6.99 | -2.86 | | | |
|
| Secondary | Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8 | The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis. | Full analysis set. A mixed model for repeated measurements (MMRM) based on observed cases was used. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline to Week 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 1 mg | Vortioxetine 1 mg, encapsulated tablets, orally, once daily for up 8 weeks. | | OG002 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up 8 weeks. |
|
| Secondary | Clinical Global Impression Scale-Global Improvement at Week 8 | The Clinical Global Impression - Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis. | Full analysis set. A mixed model for repeated measurements (MMRM) based on observed cases was used. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline to Week 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 1 mg | Vortioxetine 1 mg, encapsulated tablets, orally, once daily for up 8 weeks. | | OG002 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up 8 weeks. | | OG003 | Vortioxetine 10 mg |
|
| Secondary | Percentage of Responders in HAM-D24 Total Score at Week 8 | A responder is defined as a participant with a ≥50% decrease from Baseline in HAM-D24 total score. The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74, where a higher score indicates a greater depressive state. | Full analysis set; last observation carried forward (LOCF) was used. | Posted | | Number | | percentage of participants | | Baseline and Week 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 1 mg | Vortioxetine 1 mg, encapsulated tablets, orally, once daily for up 8 weeks. | | OG002 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up 8 weeks. | | OG003 | Vortioxetine 10 mg | |
|
| Secondary | Change From Baseline in HAM-D24 Total Score at Week 8 in Participants With Baseline HAM-A Score ≥20 | The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74 where a higher score indicates a greater depressive state. The Hamilton Anxiety Scale (HAM-A) is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (severe symptoms). LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis. | Full analysis set patients with a HAM-A Baseline score ≥ 20. A mixed model for repeated measurements (MMRM) based on observed cases was used. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline to Week 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 1 mg | Vortioxetine 1 mg, encapsulated tablets, orally, once daily for up 8 weeks. |
|
| Secondary | Percentage of Participants in MADRS Remission at Week 8 | Remission is defined as a participant with a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≤10. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement. | Full analysis set; LOCF was used. | Posted | | Number | | percentage of participants | | Week 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 1 mg | Vortioxetine 1 mg, encapsulated tablets, orally, once daily for up 8 weeks. | | OG002 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up 8 weeks. | | OG003 | Vortioxetine 10 mg | Vortioxetine 10 mg, encapsulated tablets, orally, once daily for up 8 weeks. |
|
| Secondary | Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Other Weeks Assessed | The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score range is from 0 to 74 where a higher score indicates a greater depressive state. LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis. | Full analysis set with available data at Baseline. A mixed model for repeated measurements (MMRM) based on observed cases was used; "n" indicates the number of patients included in the analysis at each time point. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline and Weeks 1, 2, 4 and 6 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 1 mg | Vortioxetine 1 mg, encapsulated tablets, orally, once daily for up 8 weeks. | | OG002 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up 8 weeks. |
|
| Secondary | Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Other Weeks Assessed | The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis. | Full analysis set with available SDS Total Score data at Baseline. A mixed model for repeated measurements (MMRM) based on observed cases was used; "n" indicates the number of patients included in the analysis at each time point. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline and Weeks 1, 2 and 6 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 1 mg | Vortioxetine 1 mg, encapsulated tablets, orally, once daily for up 8 weeks. | | OG002 | Vortioxetine 5 mg | |
|
| Secondary | Clinical Global Impression Scale-Global Improvement at Other Weeks Assessed | The Clinical Global Impression - global improvement assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis. | Full analysis set with available CGI-S data at Baseline. A mixed model for repeated measurements (MMRM) based on observed cases was used; "n" indicates the number of patients included in the analysis at each time point. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline and Weeks 1, 2, 4 and 6 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 1 mg | Vortioxetine 1 mg, encapsulated tablets, orally, once daily for up 8 weeks. | | OG002 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up 8 weeks. |
|
| Secondary | Percentage of Responders in HAM-D24 Total Score at Other Weeks Assessed | A responder is defined as a participant with a ≥50% decrease from Baseline in HAM-D24 total score. The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74, where a higher score indicates a greater depressive state. | Full analysis set with available data at Week 1; Last observation carried forward (LOCF) was used for other time points. "n" indicates the number of patients included in the analysis at each time point. | Posted | | Number | | percentage of participants | | Baseline and Weeks 1, 2, 4 and 6 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 1 mg | Vortioxetine 1 mg, encapsulated tablets, orally, once daily for up 8 weeks. | | OG002 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up 8 weeks. | |
|
| Secondary | Change From Baseline in HAM-D24 Total Score at Other Weeks Assessed in Participants With a Baseline HAM-A Score ≥20 | The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score range from 0 to 74 where a higher score indicates a greater depressive state. The Hamilton Anxiety Scale (HAM-A) is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (symptoms severe). LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis. | Full analysis set patients with a HAM-A Baseline score ≥20 and with available data at Baseline. A mixed model for repeated measurements (MMRM) based on observed cases was used; "n" indicates the number of patients included in the analysis at each time point. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline and Weeks 1, 2, 4 and 6 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 1 mg |
|
| Secondary | Percentage of Participants in MADRS Remission at Other Weeks Assessed | Remission is defined as a participant with a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≤10. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement. | Full analysis set with available data at Week 1; Last observation carried forward was used for other time points. | Posted | | Number | | percentage of participants | | Weeks 1, 2, 4 and 6 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 1 mg | Vortioxetine 1 mg, encapsulated tablets, orally, once daily for up 8 weeks. | | OG002 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up 8 weeks. | | OG003 | Vortioxetine 10 mg |
|
| Secondary | Percentage of Participants With a Sustained Response in HAM-D24 Total Score | A sustained response is defined as a ≥20% decrease from Baseline in HAM-D24 total score obtained at Week 1 and sustained through Week 7 and at least 50% decrease from Baseline at Week 8. | | Posted | | Number | | percentage of participants | | From Baseline through Week 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 1 mg | Vortioxetine 1 mg, encapsulated tablets, orally, once daily for up 8 weeks. | | OG002 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up 8 weeks. | | OG003 | Vortioxetine 10 mg | Vortioxetine 10 mg, encapsulated tablets, orally, once daily for up 8 weeks. |
| |
| Secondary | Change From Baseline in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score at Each Week | The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). A decrease in the total score or on individual items indicates improvement. LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis. | Full analysis set with available data at Baseline. A mixed model for repeated measurements (MMRM) based on observed cases was used; "n" indicates the number of patients included in the analysis at each time point. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline and Weeks 1, 2, 4, 6, and 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 1 mg | Vortioxetine 1 mg, encapsulated tablets, orally, once daily for up 8 weeks. | | OG002 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up 8 weeks. |
|
| Secondary | Change From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Each Week Assessed | The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis. | Full analysis set with available data at Baseline. A mixed model for repeated measurements (MMRM) based on observed cases was used; "n" indicates the number of patients included in the analysis at each time point. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline and Weeks 1, 2, 4, 6, and 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 1 mg | Vortioxetine 1 mg, encapsulated tablets, orally, once daily for up 8 weeks. | | OG002 |
|
| Secondary | Change From Baseline in Clinical Global Impression Scale-Severity of Illness at Each Week Assessed | The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis. | Full analysis set with available data at Baseline. A mixed model for repeated measurements (MMRM) based on observed cases was used; "n" indicates the number of patients included in the analysis at each time point. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline and Weeks 1, 2, 4, 6, and 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 1 mg | Vortioxetine 1 mg, encapsulated tablets, orally, once daily for up 8 weeks. | | OG002 |
|
| Secondary | Change From Baseline in Hospital Anxiety and Depression (HAD) Scales at Each Week Assessed | The HAD scale is completed by the participant and comprises two subscales, one measuring depression (focusing on the state of lost interest and diminished pleasure response) and one measuring anxiety (including anxious mood, restlessness, anxious thoughts, panic attacks). Each subscale is made up of 7 items that are assessed on a scale of 0 = no anxiety/depression to 3 = severe feeling of anxiety/depression. Participants are required to indicate the response which most accurately reflects the way they have felt over the last few days. Scores for the depression and anxiety subscales are summed separately and not combined, with each score ranging from 0 to 21 (maximal severity). LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis | Full analysis set with available data at Baseline. A mixed model for repeated measurements (MMRM) based on observed cases was used; "n" indicates the number of patients included in the analysis at each time point. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline and Weeks 1, 4, and 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 1 mg | Vortioxetine 1 mg, encapsulated tablets, orally, once daily for up 8 weeks. |
|
| Secondary | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Physical Functioning Subscore at All Weeks Assessed | The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The physical functioning subscale assesses limitations in physical activities because of health problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis. | Full analysis set with available SF-36 Subscore data at Baseline. A mixed model for repeated measurements (MMRM) based on observed cases was used; "n" indicates the number of patients included in the analysis at each time point. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline and Weeks 2, 4 and 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 1 mg | Vortioxetine 1 mg, encapsulated tablets, orally, once daily for up 8 weeks. | | OG002 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up 8 weeks. |
|
| Secondary | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Physical Subscore at All Weeks Assessed | The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The role-physical subscale assesses limitations in usual role activities because of physical health problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis. | Full analysis set with available SF-36 Subscore data at Baseline. A mixed model for repeated measurements (MMRM) based on observed cases was used; "n" indicates the number of patients included in the analysis at each time point. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline and Weeks 2, 4 and 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 1 mg | Vortioxetine 1 mg, encapsulated tablets, orally, once daily for up 8 weeks. | | OG002 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up 8 weeks. |
|
| Secondary | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Bodily Pain Subscore at All Weeks Assessed | The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The bodily pain sub-score scale ranges from 0 (best) - 100 (worst). LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis. | Full analysis set with available SF-36 Subscore data at Baseline. A mixed model for repeated measurements (MMRM) based on observed cases was used; "n" indicates the number of patients included in the analysis at each time point. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline and Weeks 2, 4 and 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 1 mg | Vortioxetine 1 mg, encapsulated tablets, orally, once daily for up 8 weeks. | | OG002 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up 8 weeks. |
|
| Secondary | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) General Health Subscore at All Weeks Assessed | The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The general health sub-score scale ranges from 0 (best) - 100 (worst). LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis. | Full analysis set with available SF-36 Subscore data at Baseline. A mixed model for repeated measurements (MMRM) based on observed cases was used; "n" indicates the number of patients included in the analysis at each time point. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline and Weeks 2, 4 and 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 1 mg | Vortioxetine 1 mg, encapsulated tablets, orally, once daily for up 8 weeks. | | OG002 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up 8 weeks. |
|
| Secondary | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Vitality Subscore at All Weeks Assessed | The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The vitality sub-score assesses energy and fatigue, and ranges from 0 (best) - 100 (worst). LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis. | Full analysis set with available SF-36 Subscore data at Baseline. A mixed model for repeated measurements (MMRM) based on observed cases was used; "n" indicates the number of patients included in the analysis at each time point. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline and Weeks 2, 4 and 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 1 mg | Vortioxetine 1 mg, encapsulated tablets, orally, once daily for up 8 weeks. | | OG002 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up 8 weeks. |
|
| Secondary | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Other Weeks Assessed | The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The social functioning subscale assesses limitations in social activities because of physical or emotional problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis. | Full analysis set with available SF-36 Subscore data at Baseline. A mixed model for repeated measurements (MMRM) based on observed cases was used; "n" indicates the number of patients included in the analysis at each time point. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline and Weeks 2 and 4 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 1 mg | Vortioxetine 1 mg, encapsulated tablets, orally, once daily for up 8 weeks. | | OG002 | Vortioxetine 5 mg | |
|
| Secondary | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Emotional Subscore at All Weeks Assessed | The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The role-emotional subscale assesses limitations in usual role activities because of emotional problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis. | Full analysis set with available SF-36 Subscore data at Baseline. A mixed model for repeated measurements (MMRM) based on observed cases was used; "n" indicates the number of patients included in the analysis at each time point. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline and Weeks 2, 4 and 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 1 mg | Vortioxetine 1 mg, encapsulated tablets, orally, once daily for up 8 weeks. | | OG002 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up 8 weeks. |
|
| Secondary | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Mental Health Subscore at All Weeks Assessed | The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The mental health sub-score assesses general mental health (psychological distress and well-being) and ranges from 0 (best) - 100 (worst). LS means are from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week, and week-by-treatment as factors in the analysis. | Full analysis set with available SF-36 Subscore data at Baseline. A mixed model for repeated measurements (MMRM) based on observed cases was used; "n" indicates the number of patients included in the analysis at each time point. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline and Weeks 2, 4 and 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 1 mg | Vortioxetine 1 mg, encapsulated tablets, orally, once daily for up 8 weeks. | | OG002 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up 8 weeks. |
|
| Secondary | Healthcare Resource Utilization as Assessed by the Health Economic Assessment Questionnaire. | Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors the participants' absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks. | | Posted | | Number | | participants | | Baseline and Week 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 1 mg | Vortioxetine 1 mg, encapsulated tablets, orally, once daily for up 8 weeks. | | OG002 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up 8 weeks. | | OG003 | Vortioxetine 10 mg | Vortioxetine 10 mg, encapsulated tablets, orally, once daily for up 8 weeks. |
|